InSilicoTrialsโ€™ Post

View organization page for InSilicoTrials, graphic

4,884 followers

๐—–๐—ต๐—ฎ๐—ฟ๐˜๐—ถ๐—ป๐—ด ๐—ก๐—ฒ๐˜„ ๐—›๐—ผ๐—ฟ๐—ถ๐˜‡๐—ผ๐—ป๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—–๐—น๐—ถ๐—ป๐—ถ๐—ฐ๐—ฎ๐—น ๐—ง๐—ฟ๐—ถ๐—ฎ๐—น๐˜€: ๐—œ๐—ป๐—ฆ๐—ถ๐—น๐—ถ๐—ฐ๐—ผ๐—ง๐—ฟ๐—ถ๐—ฎ๐—น๐˜€ ๐—ฎ๐˜ ๐——๐—œ๐—” ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฐ We were thrilled to participate in the DIA 2024 Global Annual Meeting in San Diego, showcasing the transformative potential of #insilicotrials, #digitaltwins, and #AI-powered predictive intelligence in #drug development. ๐ŸŒŸ ๐—œ๐—ป๐—ป๐—ผ๐˜ƒ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ง๐—ต๐—ฒ๐—ฎ๐˜๐—ฒ๐—ฟ ๐—›๐—ถ๐—ด๐—ต๐—น๐—ถ๐—ด๐—ต๐˜๐˜€: "Are Human Patients Needed for Clinical Trials, Tomorrow?" - A compelling session with Jonathan Helfgott, Adam Kaplin and our CEO Luca Emili, moderated by MaryAnne Rizk, Ph.D. ๐—ž๐—ฒ๐˜† ๐—ง๐—ฎ๐—ธ๐—ฒ๐—ฎ๐˜„๐—ฎ๐˜†๐˜€: ๐Ÿ”ธ In silico trials: Revolutionizing drug development through virtual simulations. ๐Ÿ”ธ Regulatory acceptance: FDA's growing support for in silico methods. ๐Ÿ”ธ Efficiency & accuracy: Significant time and cost savings, precise data on drug interactions. ๐ŸŒ ๐—ฅ๐—ฒ๐—ฎ๐—น-๐—ช๐—ผ๐—ฟ๐—น๐—ฑ ๐—œ๐—บ๐—ฝ๐—ฎ๐—ฐ๐˜: From pharmaceuticals to cosmetics, #insilico models are driving innovation and enhancing #patient outcomes. Attendees also visited our booth to connect with our team and receive autographed copies of โ€œ๐™๐™ค๐™ฌ๐™–๐™ง๐™™๐™จ ๐™‚๐™ค๐™ค๐™™ ๐™Ž๐™ž๐™ข๐™ช๐™ก๐™–๐™ฉ๐™ž๐™ค๐™ฃ ๐™‹๐™ง๐™–๐™˜๐™ฉ๐™ž๐™˜๐™š": co-edited by our CEO Luca Emili, this open access book provides essential guidelines for implementing #insilicotrials effectively. Get in touch to learn more about how InSilicoTrials can revolutionize your clinical trials and #drugdevelopment processes! โ„นBlog article on our participation in #DIA2024: https://lnkd.in/dbhjxumt

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics